Phathom Pharmaceuticals Stock Number Of Shares Shorted
| PHAT Stock | USD 8.87 0.10 1.11% |
Phathom Pharmaceuticals fundamentals help investors to digest information that contributes to Phathom Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phathom Stock. The fundamental analysis module provides a way to measure Phathom Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phathom Pharmaceuticals stock.
Phathom | Number Of Shares Shorted |
Phathom Pharmaceuticals Company Number Of Shares Shorted Analysis
Phathom Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Phathom Pharmaceuticals Number Of Shares Shorted | 14.66 M |
Most of Phathom Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phathom Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Phathom Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Phathom Pharmaceuticals is extremely important. It helps to project a fair market value of Phathom Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Phathom Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phathom Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phathom Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Phathom Pharmaceuticals has 14.66 M of outstending shares currently sold short by investors. This is 358.35% higher than that of the Pharmaceuticals sector and 187.68% higher than that of the Health Care industry. The number of shares shorted for all United States stocks is significantly lower than that of the firm.
Phathom Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.Phathom Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Phathom Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 770.0M | 1.1B | 727.8M | 438.9M | 468.3M | 682.0M | |
| Enterprise Value | 549.8M | 865.4M | 635.9M | 380.6M | 225.9M | 214.6M |
Phathom Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phathom Fundamentals
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (4.33) % | ||||
| Current Valuation | 448.24 M | ||||
| Shares Outstanding | 68.38 M | ||||
| Shares Owned By Insiders | 7.69 % | ||||
| Shares Owned By Institutions | 92.31 % | ||||
| Number Of Shares Shorted | 14.66 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 23.35 X | ||||
| Revenue | 682 K | ||||
| EBITDA | (159.05 M) | ||||
| Net Income | (201.59 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 139.03 M | ||||
| Debt To Equity | 2.43 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | (2.74) X | ||||
| Cash Flow From Operations | (137.58 M) | ||||
| Short Ratio | 8.61 X | ||||
| Earnings Per Share | (5.74) X | ||||
| Target Price | 25.29 | ||||
| Number Of Employees | 452 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 613.35 M | ||||
| Total Asset | 413.84 M | ||||
| Retained Earnings | (928.68 M) | ||||
| Working Capital | 358.65 M | ||||
| Net Asset | 413.84 M |
About Phathom Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.